Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of hyperthermia plus mitomycin versus repeat BCG or standard intravesical therapy for recurrent non-muscle invasive bladder cancer after prior BCG
2008-005428-99Phase 3Completed
- Sponsor
- University College London
- Start
- Jul 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mitomycin c, bcg vaccine, epirubicin and interferon alfa-2b in non-muscle-invasive bladder cancer (NMIBC) and Bladder cancer in situ (CIS) (2 arms), sponsored by University College London. Primary endpoints: Disease-free survival and Complete response rate in carcinoma in situ. Started Jul 2010; status: completed.
02
Drugs
mitomycin cbcg vaccineepirubicininterferon alfa-2b
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)Bladder cancer in situ (CIS)
Beyond the preview
Go deeper on 2008-005428-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005428-99.